Status
Conditions
Treatments
About
Recent sutdies indicate that the existence of corpus lutein in the ovary is a key point to prevent preeclampsia, and patients undergoing FET with hormone replaced cycle have no corpus lutein and the absence of corpus lutein significantly increases the risk of preeclampsia in these patients. We aim to conduct a single center randomized trial study to compare the preeclampsia rate between the natural cycle and the hormone replaced cycle in patients undergoing FET.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
840 participants in 2 patient groups
Loading...
Central trial contact
Dan Zhang, M.D. Ph.D.; Kai-Lun Hu, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal